These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 25365757)
1. Secondary prevention of cardiovascular disease with vorapaxar: a new era of 3-drug antiplatelet therapy? Krantz MJ; Kaul S JAMA Intern Med; 2015 Jan; 175(1):9-10. PubMed ID: 25365757 [No Abstract] [Full Text] [Related]
2. Vorapaxar in the secondary prevention of atherothrombotic events. Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA; N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427 [TBL] [Abstract][Full Text] [Related]
3. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition. Ungar L; Rodriguez F; Mahaffey KW Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626 [TBL] [Abstract][Full Text] [Related]
4. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar. Cheng JW Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081 [TBL] [Abstract][Full Text] [Related]
5. Vorapaxar in atherosclerotic disease management. Cheng JW; Colucci V; Howard PA; Nappi JM; Spinler SA Ann Pharmacother; 2015 May; 49(5):599-606. PubMed ID: 25680760 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Correa S; Bonaca MP; Scirica BM; Murphy SA; Goodrich EL; Morrow DA; O'Donoghue ML J Thromb Thrombolysis; 2019 Apr; 47(3):353-360. PubMed ID: 30511258 [TBL] [Abstract][Full Text] [Related]
7. Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial. Patel SM; Morrow DA; Kidd SK; Goodrich EL; Scirica BM; Bonaca MP Vasc Med; 2019 Apr; 24(2):159-161. PubMed ID: 30868939 [No Abstract] [Full Text] [Related]
8. Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. Alfredsson J; Roe MT J Am Heart Assoc; 2015 Mar; 4(3):e001897. PubMed ID: 25792126 [No Abstract] [Full Text] [Related]
9. Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome. Perez-Rivera JA; Monedero-Campo J; Cieza-Borrella C; Ruiz-Perez P Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):339-350. PubMed ID: 28135897 [TBL] [Abstract][Full Text] [Related]
10. Vorapaxar in the treatment of cardiovascular diseases. Tantry US; Bliden KP; Chaudhary R; Novakovic M; Rout A; Gurbel PA Future Cardiol; 2020 Sep; 16(5):373-384. PubMed ID: 32308016 [TBL] [Abstract][Full Text] [Related]
11. Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial. Serebruany VL; Kim MH; Hanley DF Int J Stroke; 2016 Aug; 11(6):614-7. PubMed ID: 26860124 [TBL] [Abstract][Full Text] [Related]
12. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. Moon JY; Franchi F; Rollini F; Angiolillo DJ J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918 [TBL] [Abstract][Full Text] [Related]
13. Vorapaxar for secondary stroke prevention: perspectives and obstacles. Serebruany VL; Kim MH; Fortmann SD; Hanley DF Expert Rev Neurother; 2015; 15(12):1377-82. PubMed ID: 26566105 [TBL] [Abstract][Full Text] [Related]
15. Is Vorapaxar a safe and effective antiplatelet agent for patients with prior ischaemic stroke receiving standard antiplatelet therapy? Aftab K; Kamal AK J Pak Med Assoc; 2014 Jun; 64(6):719. PubMed ID: 25252501 [No Abstract] [Full Text] [Related]
17. Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar. Baker NC; Lipinski MJ; Lhermusier T; Waksman R Circulation; 2014 Oct; 130(15):1287-94. PubMed ID: 25287768 [No Abstract] [Full Text] [Related]
18. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. Spinler SA Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255 [TBL] [Abstract][Full Text] [Related]
19. The Novel Protease-Activated Receptor 1 Antagonist Vorapaxar as a Treatment for Thrombosis in Afibrinogenemia. Tawfik B; Pollard E; Shen YM Semin Thromb Hemost; 2018 Jun; 44(4):404-406. PubMed ID: 29763961 [No Abstract] [Full Text] [Related]
20. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E; Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]